The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate

Shahryar Khaleghi, Josephine M. Ju, Abhinav Lamba, Joseph A. Murray

Research output: Contribution to journalReview article

40 Scopus citations

Abstract

Celiac disease (CD) is a common chronic immune disease triggered by gluten. Gliadin peptides pass through the epithelial layers, either paracellularly or transcellularly, to launch a potent adaptive immune response in the lamina propria. This aberrant immune response leads to diverse gastrointestinal and extra-gastrointestinal symptoms. Currently, the only treatment for CD is a strict lifelong adherence to a gluten-free diet (GFD), which can be challenging. An early effect of gluten in CD is an increase in gut permeability. Larazotide acetate, also known as AT-1001, is a synthetic peptide developed as a permeability regulator primarily targeting CD. In vitro studies indicate that larazotide acetate is capable of inhibiting the actin rearrangement caused by gliadin and clinical studies have been conducted using this peptide as a therapy for CD.

Original languageEnglish (US)
Pages (from-to)37-49
Number of pages13
JournalTherapeutic Advances in Gastroenterology
Volume9
Issue number1
DOIs
StatePublished - Jan 2016

Keywords

  • Caco-2 cells
  • gliadin
  • gluten-free diet
  • intestinal integrity
  • paracellular permeability
  • zonulin

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate'. Together they form a unique fingerprint.

  • Cite this